Brian T Fisher

List of Publications by Year in Descending Order

147 papers	2,559 citations	26 h-index	47 g-index
153 ext. papers	3,566 ext. citations	4.3 avg, IF	4.87 L-index

#	Paper	IF	Citations
147	Multicenter Prospective Study of Biomarkers for Diagnosis of Invasive Candidiasis in Children and Adolescents.. *Clinical Infectious Diseases*, **2022**,	11.6	1
146	Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation. *Pediatric Blood and Cancer*, **2022**, 69, e29384	3	0
145	The Effectiveness Of Government Masking Mandates On COVID-19 County-Level Case Incidence Across The United States, 2020.. *Health Affairs*, **2022**, 101377hlthaff202101072	0	5
144	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.. *Journal of Clinical Oncology*, **2022** , JCO2102678	2.2	3
143	Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio /ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.. *Journal of Clinical Oncology*, **2022**, JCO2101612	2.2	2
142	Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia.. *Infection Control and Hospital Epidemiology*, **2022**, 1-8	2	
141	Center Variation in Indication and Short-Term Outcomes after Pediatric Heart Transplantation: Analysis of a Merged United Network for Organ Sharing - Pediatric Health Information System Cohort. *Pediatric Cardiology*, **2021**, 1	2.1	
140	Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia. *Pediatric Blood and Cancer*, **2021**, e29467	3	0
139	Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Children's Hospital During the COVID-19 Pandemic. *Infection Control and Hospital Epidemiology*, **2021**, 1-24	2	0
138	Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. *JAMA Network Open*, **2021**, 4, e2128385	10.4	3
137	Human Adenovirus 7-Associated Hemophagocytic Lymphohistiocytosis-like Illness: Clinical and Virological Characteristics in a Cluster of Five Pediatric Cases. *Clinical Infectious Diseases*, **2021**, 73, e1532-e1538	11.6	3
136	Conventional compared to network meta-analysis to evaluate antibiotic prophylaxis in patients with cancer and haematopoietic stem cell transplantation recipients. *BMJ Evidence-Based Medicine*, **2021**, 26, 320-326	2.7	0
135	Variation in Treatment of Children Hospitalized With New-Onset Systemic Juvenile Idiopathic Arthritis in the US. *Arthritis Care and Research*, **2021**, 73, 1714-1721	4.7	1
134	Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia. *Pediatric Blood and Cancer*, **2021**, 68, e28940	3	
133	Diagnostic Challenges in Pediatric Hemophagocytic Lymphohistiocytosis. *Journal of Clinical Immunology*, **2021**, 41, 1213-1218	5.7	1
132	Musculoskeletal impairments in children receiving intensive therapy for acute leukemia or undergoing hematopoietic stem cell transplant: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2021**, 68, e29053	3	0
131	Prospective Evaluation of Galactomannan and (1-3) β-D-Glucan Assays as Diagnostic Tools for Invasive Fungal Disease in Children, Adolescents, and Young Adults With Acute Myeloid Leukemia Receiving Fungal Prophylaxis. *Journal of the Pediatric Infectious Diseases Society*, **2021**, 10, 864-871	4.8	4

130	Effect of first-line biologic initiation on glucocorticoid exposure in children hospitalized with new-onset systemic juvenile idiopathic arthritis: emulation of a pragmatic trial using observational data. *Pediatric Rheumatology*, **2021**, 19, 109	3.5	0
129	Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma. *Journal of the National Cancer Institute*, **2021**, 113, 282-291	9.7	8
128	American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. *Transplantation and Cellular Therapy* , **2021**, 27, 201-211		6
127	Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. *Transplantation and Cellular Therapy*, **2021**, 27, 177.e1-177.e8		5
126	A Randomized Trial of Caspofungin vs Triazoles Prophylaxis for Invasive Fungal Disease in Pediatric Allogeneic Hematopoietic Cell Transplant. *Journal of the Pediatric Infectious Diseases Society*, **2021**, 10, 417-425	4.8	6
125	Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents. *Journal of the Pediatric Infectious Diseases Society*, **2021**,	4.8	2
124	Fungal diagnostic testing and therapy: navigating the neutropenic period in children with high-risk leukemia. *Hematology American Society of Hematology Education Program*, **2021**, 2021, 361-367	3.1	
123	Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group. *Haematologica*, **2020**, 105, 1879-1886	6.6	39
122	Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. *Journal of Clinical Oncology*, **2020**, 38, 3205-3216	2.2	23
121	A multicenter study to define the epidemiology and outcomes of Clostridioides difficile infection in pediatric hematopoietic cell and solid organ transplant recipients. *American Journal of Transplantation*, **2020**, 20, 2133-2142	8.7	2
120	Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients. *Paediatric Drugs*, **2020**, 22, 165-188	4.2	9
119	Prophylaxis Against Invasive Fungal Disease for Neutropenic Children and Young Adults-Reply. *JAMA - Journal of the American Medical Association*, **2020**, 323, 998-999	27.4	
118	Assessment of the impact of inpatient infectious events in pediatric patients with newly diagnosed acute leukemia at Dr. Robert Reid Cabral Children's Hospital, Dominican Republic. *PLoS ONE*, **2020**, 15, e0243795	3.7	0
117	Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. *Clinical Infectious Diseases*, **2020**, 71, 226-236	11.6	27
116	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clinical Infectious Diseases*, **2020**, 71, 1367-1376	11.6	607
115	Association of Social Distancing, Population Density, and Temperature With the Instantaneous Reproduction Number of SARS-CoV-2 in Counties Across the United States. *JAMA Network Open*, **2020**, 3, e2016099	10.4	72
114	Chlorhexidine gluconate bathing in children with cancer or those undergoing hematopoietic stem cell transplantation: A double-blinded randomized controlled trial from the Children's Oncology Group. *Cancer*, **2020**, 127, 56-66	6.4	7
113	Outcomes of human adenovirus infection and disease in a retrospective cohort of pediatric solid organ transplant recipients. *Pediatric Transplantation*, **2019**, 23, e13510	1.8	3

112	Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. *Pediatric Blood and Cancer*, **2019**, 66, e27747	3	26
111	Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment. *Leukemia and Lymphoma*, **2019**, 60, 2190-2198	1.9	9
110	Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: A systematic review of randomized trials. *Cancer Medicine*, **2019**, 8, 4536-4546	4.8	28
109	Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2019**, 322, 1673-1681	27.4	33
108	Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031. *Blood*, **2019**, 134, 292-292	2.2	12
107	Rates of Laboratory Adverse Events By Chemotherapy Course for Pediatric Acute Leukemia Patients within the Leukemia Electronic Abstraction of Records Network (LEARN). *Blood*, **2019**, 134, 333-333	2.2	2
106	Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group. *Blood*, **2019**, 134, 703-703	2.2	1
105	Poverty and survival in targeted immunotherapy clinical trials.. *Journal of Clinical Oncology*, **2019**, 37, 10034-10034	2.2	1
104	1745. Retrospective Cohort Analysis to Determine the Incidence of CMV Infection and Disease in Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children's Hospital. *Open Forum Infectious Diseases*, **2019**, 6, S639-S640	1	78
103	Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. *Blood*, **2019**, 134, 379-379	2.2	1
102	Reduced Relapse Risk in Children with Acute Myeloid Leukemia (AML) Who Experience Septic Shock (SS). *Blood*, **2019**, 134, 3496-3496	2.2	
101	Inpatient Databases **2019**, 290-304		
100	Impact of Trimethoprim-sulfamethoxazole Urinary Tract Infection Prophylaxis on Non-UTI Infections. *Pediatric Infectious Disease Journal*, **2019**, 38, 396-397	3.4	3
99	Posaconazole Administration in Hospitalized Children in the United States. *Journal of the Pediatric Infectious Diseases Society*, **2019**, 8, 481-484	4.8	2
98	The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma. *British Journal of Haematology*, **2019**, 184, 684-688	4.5	2
97	The Cost of Vancomycin and Piperacillin/Tazobactam Treatment-Reply. *JAMA Pediatrics*, **2018**, 172, 494-495	8.5	2
96	Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. *Cancer Medicine*, **2018**, 7, 3-12	4.8	11
95	Identifying patient- and family-centered outcomes relevant to inpatient versus at-home management of neutropenia in children with acute myeloid leukemia. *Pediatric Blood and Cancer*, **2018**, 65, e26927	3	5

94	Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia. *Pediatric Critical Care Medicine*, **2018**, 19, e312-e320	3	6
93	Invasive Fungal Disease in Pediatric Solid Organ Transplant Recipients. *Journal of the Pediatric Infectious Diseases Society*, **2018**, 7, 219-225	4.8	15
92	Risk Factors for Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review. *Journal of the Pediatric Infectious Diseases Society*, **2018**, 7, 191-198	4.8	50
91	A Multicenter Consortium to Define the Epidemiology and Outcomes of Inpatient Respiratory Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients. *Journal of the Pediatric Infectious Diseases Society*, **2018**, 7, 275-282	4.8	41
90	Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database. *Pediatric Blood and Cancer*, **2018**, 65, e27372	3	3
89	Successful treatment of pulmonary mucormycosis in two pediatric hematopoietic stem cell transplant patients. *Pediatric Transplantation*, **2018**, 22, e13270	1.8	1
88	Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation. *Infection Control and Hospital Epidemiology*, **2018**, 39, 797-805	2	4
87	Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia. *PLoS ONE*, **2018**, 13, e0192529	3.7	12
86	Using administrative laboratory result data to describe adverse events.. *Journal of Clinical Oncology* , **2018**, 36, e18698-e18698	2.2	
85	Assessing Neighborhood Characteristics As Risk Factors for Bloodstream Infection in Children with Acute Leukemia. *Blood*, **2018**, 132, 833-833	2.2	
84	Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort. *Blood*, **2018**, 132, 624-624	2.2	
83	A Novel Approach to Identifying Septic Shock (SS) in Children with Acute Lymphoblastic Leukemia (ALL) Using Pediatric Health Information System (PHIS) Data: Methods Validation and Incidence Estimation in a National Cohort. *Blood*, **2018**, 132, 3597-3597	2.2	
82	Evaluation of Hospital Admission Patterns in Children Receiving Treatment for Acute Lymphoblastic Leukemia: What Does a Typical Leukemia Experience Look like?. *Blood*, **2018**, 132, 4763-4763	2.2	1
81	Comparative Effectiveness of Rasburicase and Allopurinol in Children with Acute Lymphoblastic Leukemia: An Emulated Pragmatic Trial Using Observational Data. *Blood*, **2018**, 132, 830-830	2.2	
80	Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia. *Blood*, **2018**, 132, 369-369	2.2	1
79	Retrospective review of immunocompromised children undergoing skin biopsy for suspected invasive infection: Analysis of factors predictive of invasive mold. *Pediatric Dermatology*, **2018**, 35, 104-111	1.9	6
78	Complete Versus Staged Repair for Neonates With Tetralogy of Fallot: Establishment and Validation of a Cohort of 2235 Patients Using Detailed Surgery Sequence Review of Health Care Administrative Data. *Medical Care*, **2018**, 56, e76-e82	3.1	3
77	Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2018**, 320, 995-1004	27.4	86

76	Using electronic medical record data to report laboratory adverse events. *British Journal of Haematology*, **2017**, 177, 283-286	4.5	21
75	The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. *American Journal of Hematology*, **2017**, 92, 141-148	7.1	21
74	Diagnostic Imaging and Invasive Fungal Diseases in Children. *Journal of the Pediatric Infectious Diseases Society*, **2017**, 6, S22-S31	4.8	32
73	Complications preceding early deaths in Black and White children with acute myeloid leukemia. *Pediatric Blood and Cancer*, **2017**, 64, e26712	3	2
72	Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children. *JAMA Pediatrics*, **2017**, 171, e173219	8.3	45
71	Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database. *PLoS ONE*, **2017**, 12, e0186960	3.7	5
70	Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. *Journal of Clinical Oncology*, **2017**, 35, 2082-2094	2.2	213
69	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. *Haematologica*, **2017**, 102, e340-e343	6.6	4
68	Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children. *Journal of the Pediatric Infectious Diseases Society*, **2017**, 6, S32-S44	4.8	39
67	International Collaborative on Contemporary Epidemiology and Diagnosis of Invasive Fungal Disease in Children. *Journal of the Pediatric Infectious Diseases Society*, **2017**, 6, S1-S2	4.8	3
66	Galactomannan, Ð-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. *Clinical Infectious Diseases*, **2016**, 63, 1340-1348	11.6	93
65	Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals. *Cancer*, **2016**, 122, 3394-3400	6.4	5
64	Administration of Palivizumab in the NICU. *Hospital Pediatrics*, **2016**, 6, 354-8	2.5	1
63	T2Candida Provides Rapid and Accurate Species Identification in Pediatric Cases of Candidemia. *American Journal of Clinical Pathology*, **2016**, 145, 858-61	1.9	44
62	Volume-Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 404-410.e1	2	7
61	The Changing Landscape for Paediatric Regulation of Pharmaceutical Agents with a Focus on Antifungal Agents. *Current Fungal Infection Reports*, **2016**, 10, 1-6	1.4	2
60	Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 223-229.e2	2	7
59	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. *Journal of Clinical Oncology*, **2016**, 34, 1537-43	2.2	35

58	A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. *Leukemia and Lymphoma*, **2016**, 57, 1567-74	1.9	9
57	Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States. *PLoS ONE*, **2016**, 11, e0151362	3.7	5
56	A quality improvement initiative to increase pneumococcal vaccination coverage among children after kidney transplant. *Pediatric Transplantation*, **2016**, 20, 783-9	1.8	12
55	Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States. *British Journal of Haematology*, **2016**, 174, 591-9	4.5	11
54	Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database. *Pediatric Blood and Cancer*, **2016**, 63, 901-7	3	7
53	Comparative effectiveness of fungicidal vs. fungistatic therapies for the treatment of paediatric candidaemia. *Mycoses*, **2016**, 59, 173-8	5.2	4
52	Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report. *Cancer Medicine*, **2016**, 5, 2412-6	4.8	4
51	Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12). *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 3536-3539	5.1	27
50	A Prospective, International Cohort Study of Invasive Mold Infections in Children. *Journal of the Pediatric Infectious Diseases Society*, **2015**, 4, 313-22	4.8	67
49	Staphylococcus aureus bacteremia in hospitalized children: incidence and outcomes. *Infection Control and Hospital Epidemiology*, **2015**, 36, 603-5	2	19
48	Classification of treatment-related mortality in children with cancer: a systematic assessment. *Lancet Oncology, The*, **2015**, 16, e604-10	21.7	51
47	A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. *Cancer Medicine*, **2015**, 4, 1356-64	4.8	11
46	Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2015**, 62, 1184-9	3	10
45	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2015**, 62, 1775-81	3	19
44	Suspected posaconazole toxicity in a pediatric oncology patient. *Pediatric Blood and Cancer*, **2015**, 62, 1682	3	23
43	Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia. *Journal of the Pediatric Infectious Diseases Society*, **2015**, 4, 290-6	4.8	6
42	Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis. *Journal of Clinical Oncology*, **2015** , 33, 501-9	2.2	89
41	Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. *PLoS ONE*, **2015**, 10, e0143480	3.7	13

40	Accuracy of adverse event reporting on a phase III clinical trial for pediatric acute myeloid leukemia: A report from the Children Oncology Group.. *Journal of Clinical Oncology*, **2015**, 33, 10028-10028	2.2	
39	Resource utilization (RU) and toxicities after carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel) for autologous stem cell rescue (ASCR) in high-risk neuroblastoma (HRNB).. *Journal of Clinical Oncology*, **2015**, 33, e21009-e21009	2.2	
38	Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction. *Blood*, **2015**, 126, 530-530	2.2	
37	Management of invasive fungal infections in the pediatric intensive care unit. *Journal of Pediatric Intensive Care*, **2014**, 3, 269-279	1	
36	Infectious diseases approach to immunocompromised patients in the pediatric intensive care unit. *Journal of Pediatric Intensive Care*, **2014**, 3, 305-313	1	0
35	Pneumocystis Pneumonia: Epidemiology and Options for Prophylaxis in Non-HIV Immunocompromised Pediatric Patients. *Current Fungal Infection Reports*, **2014**, 8, 45-55	1.4	2
34	Variation in Risk of Hospital-Onset Clostridium difficile Infection Across -Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. *Journal of the Pediatric Infectious Diseases Society*, **2014**, 3, 329-35	4.8	15
33	Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. *Pediatric Blood and Cancer*, **2014**, 61, 68-73	3	9
32	Establishing a high-risk neuroblastoma cohort using the Pediatric Health Information System Database. *Pediatric Blood and Cancer*, **2014**, 61, 1129-1131	3	12
31	1074Immunization Practices of Pediatric Oncology Providers Towards Children with Acute Lymphoblastic Leukemia that have Completed Chemotherapy. *Open Forum Infectious Diseases*, **2014**, 1, S315-S315	1	1
30	1444Comparative effectiveness of fungicidal vs fungistatic therapies for the treatment of pediatric candidemia. *Open Forum Infectious Diseases*, **2014**, 1, S380-S380	1	
29	Identification of a novel intertypic recombinant species D human adenovirus in a pediatric stem cell transplant recipient. *Journal of Clinical Virology*, **2014**, 61, 496-502	14.5	10
28	Association of weekend admission with hospital length of stay, time to chemotherapy, and risk for respiratory failure in pediatric patients with newly diagnosed leukemia at freestanding US children's hospitals. *JAMA Pediatrics*, **2014**, 168, 925-31	8.3	20
27	Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data.. *Journal of Clinical Oncology*, **2014**, 32, 10069-10069	2.2	3
26	Variation in antibiotic use in pediatric acute lymphoblastic leukemia (ALL) by hospital pediatric volume.. *Journal of Clinical Oncology*, **2014**, 32, e17703-e17703	2.2	
25	Impact of weekend admission on hospital length of stay and organ failure in pediatric leukemia patients at free-standing U.S. children hospitals.. *Journal of Clinical Oncology*, **2014**, 32, 6598-6598	2.2	
24	Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Children Oncology Group.. *Journal of Clinical Oncology*, **2014**, 32, 7086-7086	2.2	
23	Broncho-Alveolar Lavage and Lung Biopsy in Patients with Hematological Malignancy and Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review and Meta-Analysis. *Blood* , **2014**, 124, 2628-2628	2.2	

22	Resource Utilization and Cost Analysis By Treatment Arm on the Children's Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children's Oncology Group. *Blood*, **2014**, 124, 210-210	2.2	
21	Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States. *Blood*, **2014**, 124, 553-553	2.2	1
20	The Role of Biomarkers for Diagnosis of and Therapeutic Decisions Related to Invasive Aspergillosis in Children. *Current Fungal Infection Reports*, **2013**, 7, 7-14	1.4	11
19	Variation in hospital antibiotic prescribing practices for children with acute lymphoblastic leukemia. *Leukemia and Lymphoma*, **2013**, 54, 1633-9	1.9	17
18	Trends in Clostridium difficile infection and risk factors for hospital acquisition of Clostridium difficile among children with cancer. *Journal of Pediatrics*, **2013**, 163, 699-705.e1	3.6	53
17	Pediatric Risk Factors for Candidemia Secondary to Candida glabrata and Candida krusei Species. *Journal of the Pediatric Infectious Diseases Society*, **2013**, 2, 263-6	4.8	7
16	Avascular Necrosis(AVN) and Surgical Intervention In Pediatric Acute Lymphoblastic Leukemia(ALL): A Retrospective Cohort Analysis From The Pediatric Health Information Systems (PHIS). *Blood*, **2013** , 122, 1689-1689	2.2	1
15	Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group. *Blood*, **2013**, 122, 931-931	2.2	1
14	Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. *Pediatric Blood and Cancer*, **2012**, 59, 11-5	3	8
13	Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. *Journal of the Pediatric Infectious Diseases Society*, **2012**, 1, 103-11	4.8	33
12	Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric cancer patients.. *Journal of Clinical Oncology*, **2012**, 30, 1504-1504	2.2	
11	Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States. *Blood*, **2012**, 120, 4283-4283	2.2	
10	Dexrazoxane Use in Pediatric Patients with Acute Lymphoblastic or Myeloid Leukemia: Analysis of a National Cohort of Patients in the Pediatric Health Information Systems Database From 1999 to 2009. *Blood*, **2011**, 118, 4242-4242	2.2	
9	Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. *Blood*, **2011**, 118, 2617-2617	2.2	
8	Hospitalizations for coccidioidomycosis at forty-one children's hospitals in the United States. *Pediatric Infectious Disease Journal*, **2010**, 29, 243-7	3.4	29
7	Risk factors for renal failure in pediatric patients with acute myeloid leukemia: a retrospective cohort study. *Pediatric Blood and Cancer*, **2010**, 55, 655-61	3	28
6	Induction Mortality In Pediatric Acute Lymphoblastic Leukemia (ALL): a Retrospective Cohort Analysis From the Pediatric Health Systems Information (PHIS) Database, 1999–2009. *Blood*, **2010**, 116, 3239-3239	2.2	
5	Cefepime and mortality in pediatric acute myelogenous leukemia: a retrospective cohort study. *Pediatric Infectious Disease Journal*, **2009**, 28, 971-5	3.4	12

4	Antibiotic use in pediatric patients admitted to a referral hospital in Botswana. *American Journal of Tropical Medicine and Hygiene*, **2009**, 81, 129-31	3.2	2
3	Treatment of invasive candidiasis in immunocompromised pediatric patients. *Paediatric Drugs*, **2008** , 10, 281-98	4.2	12
2	Caspofungin for the treatment of pediatric fungal infections. *Pediatric Infectious Disease Journal*, **2008**, 27, 1099-102	3.4	14
1	In-Hospital Databases244-258		7